Mesothelioma other diagnostic studies

Mesothelioma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mesothelioma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Other Imaging Findings
Treatment
Medical Therapy
Surgery
Summary of Treatment for Pleural Mesothelioma
Summary of Treatment for Peritoneal Mesothelioma
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mesothelioma other diagnostic studies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mesothelioma other diagnostic studies All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mesothelioma other diagnostic studies
CDC on Mesothelioma other diagnostic studies
Mesothelioma other diagnostic studies in the news
Blogs on Mesothelioma other diagnostic studies
Directions to Hospitals Treating Mesothelioma
Risk calculators and risk factors for Mesothelioma other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

• Antibodies to cytokeratin proteins are positive, differentiating these neoplasms from many sarcomas but not adenocarcinomas.
• The absence of staining with CEA or Leu-M1 differentiates them from adenocarcinomas.
• Recent evidence shows that Wilms’ Tumor Antigen 1 may help differentiate mesothelioma from adenocarcinoma.

Other Diagnostic Studies

Position Emission Tomography

• Positron emission tomography is becoming useful in two clinical settings:

• Differentiating between benign and malignant asbestos-related pleural thickening
• Assessing for nodal metastases

• In addition, there appears to be a correlation between the degree of FDG uptake and the biological aggressiveness of the tumor, which may help to guide treatment.